Shares of Aurobindo Pharma Ltd surged 1.34% on Friday as the company’s wholly-owned subsidiary, CuraTeQ Biologics Private Ltd, received a positive opinion for its biosimilar Zefylti from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
The CHMP recommended the marketing authorisation of Zefylti (BP13), a filgrastim biosimilar, intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells (PBPCs).
In a regulatory filing, Aurobindo Pharma confirmed the biosimilar Zefylti will be available in 30 MU/0.5 mL and 48 MU/0.5 mL formulations, marking a significant milestone for its European expansion.
The EMA opinion follows Aurobindo’s GMP certification in November, with two additional biosimilars, pegylated filgrastim (BP14) and trastuzumab (BP02), currently under review. Another product, a biosimilar of bevacizumab (BP01), is under review with the MHRA.
Key Stock Highlights:
- Current Price: ₹1,224.55
- Day’s Gain: 1.34% (+₹16.15)
- 1-Year Performance: Up 16.57%
- 5-Year Performance: Up 172.62%
| Day | Open | Close | Change % |
|---|---|---|---|
|
Fri, Dec 13 2024
|
₹1,216.10
|
₹1,208.40
|
-0.51%
|
|
Thu, Dec 12 2024
|
₹1,231.10
|
₹1,214.60
|
-0.92%
|
|
Wed, Dec 11 2024
|
₹1,236.00
|
₹1,225.85
|
-0.91%
|
|
Tue, Dec 10 2024
|
₹1,241.10
|
₹1,237.10
|
-0.19%
|
|
Mon, Dec 9 2024
|
₹1,247.45
|
₹1,239.50
|
-0.54%
|
|
Fri, Dec 6 2024
|
₹1,250.10
|
₹1,246.20
|
|
|
Thu, Dec 5 2024
|
₹1,266.00
|
₹1,243.65
|
-1.25%
|
|
Wed, Dec 4 2024
|
₹1,269.70
|
₹1,259.40
|
-0.39%
|
Disclaimer:
The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
